Investor Information


Neurogen Corporation

45 NE Industrial Rd.
Branford, CT 06405

203.488.8201 phone
203.488.4863 fax

PROGRAMS - Compound Development

Neurogen's lead clinical development programs are in Parkinson's disease and Restless legs syndrome (RLS) with its dopamine partial agonist, aplindore. The partial agonist and controlled release properties of aplindore provide the potential for improved tolerability and dosing flexibility over existing therapeutics.

More >>
Restless Legs SyndromeParkinson's Disease